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Abstract
Previous subtyping of thromboxane A2 (TXA2) receptors in platelets and vascular smooth muscle cells was based on
pharmacological criteria. Two distinct carboxy-terminal splice variants for TXA2 receptors exist and they couple to several
different G protein K subunits including GK13, but it has not been established whether either or both isoforms interact with
and signal through it. We sought to determine: (1) which TXA2 receptor isoforms exist in vascular smooth muscle, (2) if
GK13 is present in vascular smooth muscle and (3) if GK13 interacts with either or both of the two TXA2 receptor isoforms as
determined by changes in ligand binding properties and generation of intracellular signals. Both TXA2 receptor isoforms and
GK13 were found in vascular smooth muscle cells. Both the alpha and beta isoforms of the TXA2 receptors were transiently
transfected with or without GK13 into COS-7 (radioligand binding assays) or CHO cells (agonist induced Na/H exchange).
Co-expression of each receptor isoform with GK13 significantly (P6 0.05) increased the affinity of each receptor for the two
agonists, I-BOP and ONO11113, and decreased the affinity of the receptor for the antagonists, SQ29,548 and L657,925.
I-BOP stimulated Na/H exchange in vascular smooth muscle cells. Co-expression of GK13 with each TXA2 receptor
isoform in CHO cells resulted in a significant (P6 0.04) agonist induced increase in Na/H exchange compared to cells not
transfected with GK13. The results support the possibility that the previous classification of TXA2 receptor subtypes based on
pharmacological criteria reflect unique interactions with specific G protein K subunits. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Thromboxane A2 (TXA2) receptors are members
of the G protein coupled class of receptors. The pres-
ence of distinct subtypes of TXA2 receptors in plate-
lets and vascular smooth muscle was postulated by
Mais et al. [1,2] based on di¡erences in the rank
order potency for a series of 13-azapinane TXA2
receptor antagonists to antagonize TXA2 mimetic
induced platelet aggregation and contraction of
blood vessels. Further support for these subtypes
was obtained by Masuda et al. [3] who found di¡er-
0167-4889 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 9 9 ) 0 0 0 6 8 - 3
Abbreviations: CHO, Chinese hamster ovary; ECAR, extra-
cellular acidi¢cation rate; I-BOP, [1S-[1K,2K(Z),3L(1E,3S*),4K]]-
7-[3-[3-hydroxy-4-[4-iodophenoxy]-1-butenyl]-7-oxabicyclo[2.2.1]-
hept-2-yl] 5-heptenoic acid; TXA2, thromboxane A2
* Corresponding author. Fax: +1-843-792-0816;
E-mail : halushpv@musc.edu
BBAMCR 14496 29-6-99
Biochimica et Biophysica Acta 1450 (1999) 288^296
www.elsevier.com/locate/bba
ences in rank order potencies for a series of TXA2
agonists and antagonists in washed rat platelets and
rat aortic smooth muscle cells using competition ra-
dioligand binding assays. Other investigators have
also provided pharmacological or biochemical evi-
dence for a platelet and a vascular subtype of
TXA2 receptors [4^6]. Within the platelet there are
two di¡erent a⁄nity states for TXA2 receptors
[4,5,7]. The high a⁄nity state of the TXA2 receptors
is associated with platelet shape change and is
thought to be similar to the vascular subtype [4^6].
The lower a⁄nity receptor is associated with aggre-
gation and thought to represent the unique platelet
subtype [4^6,8,9]. However, the notion of distinct
subtypes is felt to be inconsistent with the observa-
tions that the receptor has only one mRNA species
[10] and only one gene for the human TXA2 receptor
[11].
A carboxy-terminal splice variant of the original
human TXA2 receptor has been cloned [12]. The
original cloned receptor has been designated the al-
pha isoform [10] and the splice variant, the beta iso-
form [12]. The alpha isoform has been found in pla-
telets, placenta and lung and the beta has been found
in endothelial cells and most recently in platelets
[10,12,13]. However, it is not known which of these
two or perhaps another isoform may be present in
human vascular smooth muscle cells. The existence
of these two isoforms, however, does not resolve the
con£ict concerning the two subtypes of receptors,
since the putative ligand binding domains for the
two isoforms are the same. Thus, another explana-
tion must be sought for the original observations
that led to the notion that subtypes of TXA2 recep-
tors exist [1,2].
TXA2 receptors have been found to couple to sev-
eral di¡erent G protein K subunits. It appears that
both isoforms couple to GKq in platelets which re-
sults in stimulation of phospholipase C [14], increases
in intracellular free calcium and many other signal-
ling events and platelet aggregation [9]. In vascular
smooth muscle cells, stimulation of TXA2 receptors
results in increases in phospholipase C activity and
intracellular free calcium in addition to proliferation
and hypertrophy [15,16]. Agonist stimulation of both
subtypes results in an increase in cAMP formation
presumably through GKs [13,17], however, the exact
mechanism has not been established. In contrast, evi-
dence has been presented that the beta isoform can
couple to GKi2, and decrease cAMP formation in
platelets and Chinese hamster ovary (CHO)
cells[18,19]. Most recently, evidence has been pro-
vided that platelet TXA2 receptors may also signal
through GK13, based on agonist induced photoa⁄n-
ity labelling of GK13 [20]. Signalling through GK13
results in Na/H exchange and intracellular alkalin-
ization [21^23]. This is an early event in platelet ac-
tivation that is induced by TXA2 agonists [8,9,24]
and thought to be associated with shape change
and the high a⁄nity state of platelet TXA2 receptors.
It was recently shown that co-transfection of the
alpha isoform of the human TXA2 receptor with
GK13 or GKq into COS-7 cells produced an increase
in a⁄nity of the receptor for the agonist I-BOP [25].
This resulted in a change in the a⁄nity state that
approached the high a⁄nity receptor seen in platelets
which, as noted above, is felt to be the same as the
vascular receptor. Since the beta isoform was re-
cently found in the platelet, this raised the possibility
that it may also be present in human vascular
smooth muscle cells.
In this study, we sought to determine: (1) which of
the isoforms of the TXA2 receptor are present in
vascular smooth muscle cells; (2) if TXA2 receptors
signal through GK13 and (3) if GK13 a¡ects the ligand
recognition properties of the two isoforms.
2. Materials and methods
The transient expression vector pcDNA3 was
purchased from Invitrogen (Carlsbad, CA). The al-
pha isoform of the TXA2 receptor was ampli¢ed
using RT-PCR from an HEL cell line and inserted
into the pcDNA3 vector [25]. The following were
generous gifts, the beta isoform, Dr. Anthony
Ware, Harvard Medical School [12]; full length
GK13, Dr. Mel Simon, California Institute of Tech-
nology; human cDNA GKq, Dr. Juan Codina and
Dr. Lutz Birnbaumer, Baylor College of Medicine,
Houston, TX; GKi2 cDNA, Dr. Steven Lanier, Med-
ical University of South Carolina, Charleston, SC.
[1S-[1K,2K(Z),3L(1E,3S*),4K]]-7-[3-[3-hydroxy-4-[4-
iodophenoxy]-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]
5-heptenoic acid (I-BOP) and [125I]BOP were synthe-
sized in our laboratory as previously described [7].
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The stereoselective TXA2 receptor antagonists (3)
L657,925 and (+) L657,926 were from Merck Frosst
Canada, Inc., Point Claire-Dorval, Quebec, Canada.
The TXA2 antagonist SQ29,548 was from Dr. Mar-
tin Ogletree, Squibb Institute for Medical Research.
Dulbecco’s modi¢ed Eagle’s medium (DMEM) was
from Gibco-BRL (Grand Island, NY). Serum Plus
and the antibiotic/antimycotic solution were from
JRH Biosciences (Lenexa, KS). All other chemicals
unless otherwise stated were from Sigma Chemical
Co. (St. Louis, MO).
2.1. Cell culture
The COS-7 cells were maintained at 37‡C in a
humidi¢ed atmosphere of 95% O2 and 5% CO2: Cells
were grown in 10 ml DMEM with 10% Serum Plus
and 1% antibiotic/antimycotic solution. Upon reach-
ing con£uence, the COS-7 cells were trypsinized with
3.0 ml of 0.05% trypsin-EDTA (Gibco-BRL) and
replated at a dilution of 1:2 or 1:3.
The CHO cell line was used for the microphysiom-
eter signalling experiments [26,27]. CHO cells were
maintained in Ham’s F12K medium with 10% fetal
calf serum/1% antibiotic/antimycotic solution.
Human vascular smooth muscle cells (ATCC
CRL-1999) were cultured in Kaighn’s modi¢cation
of F12K medium containing 10% fetal bovine serum
and 1% antibiotic/antimycotic solution. The follow-
ing were added to the medium: HEPES 10 mM, TES
10 mM, ascorbic acid 50 Wg/ml, insulin 10 Wg/ml,
transferrin 10 Wg/ml, sodium selenite 10 ng/ml, and
endothelial cell growth supplement 30 Wg/ml. After
10^14 days the cells were harvested and crude
membranes were prepared for immunoblotting for
GK13.
Rat aortic smooth muscle cells were cultured using
previously described methods [3].
2.2. Transfection and co-transfections
COS-7 cells were chosen for the radioligand bind-
ing assays because of our previous experience and
their high level of expression [25]. COS-7 cells were
split 1:2, 24 h prior to transfection. Either the alpha
(2.5 Wg) or beta isoforms (10 Wg) of the TXA2 recep-
tor cDNAs were transfected into a plate of con£uent
cells using the DEAE-dextran technique [25]. All G
protein cDNAs (GK13, GKq and GKi2) were trans-
fected at a concentration of 5 Wg/plate. Brie£y, three
con£uent plates were chosen and washed twice with
warm phosphate bu¡ered saline (PBS). A DMEM/
DEAE-dextran solution (6 ml) containing 2.5 mg/ml
DEAE-dextran and no Serum Plus was combined
with the DNA at the speci¢ed concentration and
carefully added to each of three plates. The cells
were then incubated for 4 h at 37‡C. The cocktail
was aspirated and the cells shocked with 3 ml of a
10% DMSO solution for 3 min at room temperature.
Upon aspiration, 6 ml of chloroquine (0.1 mM) was
added and incubated for 2 h, removed and the cells
were washed twice with warm PBS. The cells were
maintained in 10 ml of DMEM with 10% Serum Plus
at 37‡C, washed and fed at 24 h and harvested at
72 h.
CHO cells were used for the microphysiometry
experiments because their Na/H exchange proper-
ties have been previously well characterized [26,27].
CHO cells were transfected using a lipofectamine
(1 Wg/Wl) (Gibco) based method. One day prior to
transfection the cells were split to reach a con£uence
of 60^80%. Lipofectamine was diluted 10-fold in se-
rum free media (Ham’s F12K) and 60 Wl was used
for a 100 mm dish. cDNA (5 Wg) for each TXA2
receptor and GK13 were diluted in Ham’s F12K
(300Wl) and mixed with an equal volume of the lipo-
fectamine suspension. The solutions were incubated
for 15 min at room temperature and diluted to a
total volume of 8 ml. A 1 ml aliquot of the solution
was added to each well, incubated for 2 h, aspirated
and replaced with fresh medium and incubated over-
night. The following day they were trypsinized and
replated onto transwell cups (Costar), incubated for
a further 24 h and were studied.
2.3. Radioligand binding assays
COS-7 cells were grown for 72 h following trans-
fection and washed twice with warm PBS. The cells
were scraped into ice-cold lysis bu¡er containing
25 mM HEPES (pH 6.5), 2 mM EDTA, 10 WM in-
domethacin, 0.01 M benzamidine and 128 Wg/ml
PMSF. The membranes were homogenized (10U)
with a Dounce homogenizer and pelleted at
100 000Ug for 40 min at 4‡C. The supernatant was
removed and the pellet resuspended in 2 ml ice-cold
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incubation bu¡er containing 25 mM HEPES (pH
6.5), 150 mM NaCl, 10 mM MgCl2, 5 mM KCl,
10 WM indomethacin, 0.01 M benzamidine and 128
Wg/ml PMSF, homogenized (10U) a second time and
kept on ice until used in the assay. Proteins were
quanti¢ed with the Bio-Rad protein assay system
(Hercules, CA).
The radioligand binding studies were performed in
a ¢nal volume of 200 Wl in 12U75 mm silanized glass
tubes using previously described conditions [25].
Brie£y, transfected COS-7 cell membrane proteins
(2.5 Wg) were resuspended in ice-cold incubation
bu¡er. All components were assembled on ice and
then placed directly into the 30‡C water bath for
1 h. [125I]BOP was added at a concentration of
25 000^50 000 cpm/tube. In all binding and competi-
tion experiments, to determine the amount of non-
speci¢c binding a large excess of the TXA2 receptor
antagonist, L657,925 (10 WM), was included. This
quantity was subtracted from the total binding to
give speci¢c binding. Using a Brandel Harvester
(Gaithersburg, MD), the reactions were rapidly ter-
minated with four washes of ice-cold incubation bu¡-
er and ¢ltered through Whatman GC/F (FPD-200)
glass ¢lters. The radioactivity contained in the mem-
branes was quantitated with a Wallac LKB gamma
counter (Gaithersburg, MD).
2.4. Microphysiometry
Na/H exchange was measured in real time as
the rate of decrease in extracellular pH (extracellular
acidi¢cation rate) using a Cytosensor microphysiom-
eter [28] (Molecular Devices, Sunnyvale, CA) as pre-
viously described [26,27]. CHO cells were transfected
with the cDNAs for the alpha or beta isoforms of the
TXA2 receptors with or without the cDNA for GK13.
On the day of study a full concentration-response
curve for I-BOP was generated in triplicate or quad-
ruplicate wells. The responses for each of the wells
(3^4) were averaged to give a mean response for each
concentration of I-BOP.
2.5. Immunoblot
The Western blot performed to ascertain the pres-
ence of GK13 used a previously described method
[25,29].
2.6. Cloning of a partial cDNA from human vascular
smooth muscle cells
2.6.1.. RT-PCR
Total RNA was extracted from human aortic
smooth muscle cells with TRIzol reagent (Gibco-
BRL). First strand cDNA synthesis was carried out
according to the manufacturer’s recommendations.
Total RNA (2 Wg) was combined with 500 nM poly-
(A) speci¢c Adapter Primer (Gibco-BRL) and
sterile diethylpyrocarbonate-treated water (12 Wl to-
tal vol.) at 4‡C. The RNA-primer mix was denatured
at 70‡C for 10 min and placed on ice. A mixture
(7 Wl) that gave a ¢nal reaction composition of
20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM
MgCl2, 10 mM DTT and 500 WM each dATP,
dCTP, dGTP, dTTP was added and the primers
annealed at 42‡C for 5 min. Superscriptase II (200
units) reverse transcriptase was added and the reac-
tion continued for 60 min at 42‡C. The enzyme was
heat inactivated at 70‡C for 15 min. The mRNA was
degraded with 2 units of RNase H at 37‡C for
20 min.
2.6.2. 3P RACE and PCR ampli¢cation
For the 3P RACE and PCR ampli¢cation a nested
primer approach was undertaken. Primers corre-
sponding to known TXA2 isoforms and the poly(A)
speci¢c primers, Abridged Universal Adapter Primer
(AUAP) and Universal Adapter Primer (UAP) sup-
plied with the 3P RACE kit (Gibco-BRL) were uti-
lized. The primer sequences were as follows:
P584 5P-GGA GCC ATG TGG CCC AAT
GGC-3P, 36 to +15
GSP2 5P-GTC TTC ATC GCC CAG ACA
GTG-3P, +787 to +808
P532 5P-GGC GGG AGG GGC GCT CTG-3P,
+1058 to +1041 (speci¢c for alpha isoform)
3T2 5P-CAG GGT CAA AGA GCA TGC AA-
3P, +1147 to +1127 (speci¢c for beta isoform)
First strand cDNA (1 Wl of the reverse transcribed
reaction) was used as a template in the ¢rst round 3P
RACE. First round ampli¢cation was carried out
with P584 and AUAP primers. First round products
were diluted 1:20 in sterile water and 1 Wl was used
as template for second round 3P RACE with the
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primers GSP2 and UAP. For the third round ampli-
¢cation, second round products were diluted 1:20 in
sterile water and used as templates along with the
primers GSP2 and P532 or GSP2 and 3T2.
For both 3P RACE and PCR ampli¢cation, the
hot start method was employed. All reagents were
assembled on ice and placed directly into the pre-
heated cycler. Final reaction composition consisted
of 5% DMSO, 200 nM each primer, 200 WM each
dNTP, 1.5 mM MgCl2 and 2.5 units of Taq polymer-
ase. Ampli¢cation was as follows; 98‡C for 5 min,
75‡C for 1 min, addition of Taq, 30 cycles of 94‡C
for 1 min, 57‡C for 1 min, 72‡C for 3 min and 1 cycle
72‡C for 15 min. The ampli¢cation products were
run on a 1.2% agarose gel. The products correspond-
ing to the predicted size were excised and sequenced
using the Sanger dideoxy chain terminal method
(MUSC nucleic acid facility).
2.7. Data analysis
For the calculation of binding a⁄nities (Kd) and
receptor density (Bmax), data were analyzed accord-
ing to the method of Scatchard (Scatchard, 1949)
using the Ligand computer program (Munson and
Rodbard, 1980). The IC50 values were calculated us-
ing a two-ligand analysis with the same Ligand com-
puter program.
All radioligand binding and competition experi-
ments were performed in duplicate and statistical
analysis was performed with StatWorks software
(Cricket Software Inc., Philadelphia, PA). The bind-
ing data were analyzed using the Student’s paired t-
test. The microphysiometry data were analyzed using
an ANOVA (StatWorks). All data are expressed as
the mean þ S.E.M.
3. Results
3.1. Western blot
Although it was previously shown that GK13 has a
wide tissue distribution, its presence in human vas-
cular smooth muscle cells has not been established
[30,31]. In order to test the hypothesis that GK13
could interact with TXA2 receptors in vascular
smooth muscle cells, a Western blot for GK13 was
performed on crude membranes prepared from hu-
man vascular smooth muscle cells. GK13 was detected
in the smooth muscle cell membranes and it migrated
to the same molecular size as recombinant GK13 ex-
pressed in COS-7 cells (Fig. 1).
3.2. Cloning of the partial cDNAs for TXA2 receptor
isoforms in human vascular smooth muscle cells
Using primers speci¢c for the alpha and beta iso-
forms of the human TXA2 receptors, partial length
cDNAs for the alpha and beta receptor isoforms
were obtained by PCR (Fig. 2). The PCR products
were of the predicted size [13] and sequence (data not
Fig. 1. Western blot analysis of a crude membrane preparation
of human vascular smooth muscle cells. The membranes were
subjected to SDS-PAGE followed by transfer to nitrocellulose
and subsequent immunoblotting with an antiserum speci¢c for
GK13. Lane A contains 40 Wg of human vascular smooth
muscle cell membranes. Lane B contains 5 Wg of COS-7 cell
membranes that were transfected with the cDNA for GK13. Un-
transfected COS-7 cells do not give a positive signal for GK13
(Becker and Halushka, unpublished data).
Table 1
Kd (I-BOP) and IC50 (ONO11113) values (nM) for these two
agonists in the absence or presence of GK13 in COS-7 cells
TXA2 receptor isoform 3GK13 +GK13
alpha
I-BOP (n = 7) 2.3 þ 0.3 1.9 þ 0.4**
ONO11113 (n = 5) 2.7 þ 0.4 1.9 þ 0.3*
beta
I-BOP (n = 6) 3.5 þ 0.6 2.1 þ 0.3**
ONO11113 (n = 4) 2.2 þ 0.2 1.1 þ 0.05**
*P6 0.05, **P6 0.02, compared to 3GK13.
BBAMCR 14496 29-6-99
K.P. Becker et al. / Biochimica et Biophysica Acta 1450 (1999) 288^296292
shown). Thus, as is the case for platelets, human
vascular smooth muscle cells express the mRNA
for both isoforms of the TXA2 receptor.
3.3. Ligand binding
Having obtained evidence that both the alpha and
beta isoforms of the TXA2 receptors are expressed in
human vascular smooth muscle cells, we sought to
investigate the e¡ects of GK13 on the a⁄nity of the
TXA2 receptor isoforms for the agonist I-BOP. In
particular, could GK13 increase the a⁄nity of the
TXA2 receptors for I-BOP mimicking the high a⁄n-
ity subtype? cDNA for GK13 was co-transfected with
each of the two TXA2 receptor isoforms into COS-7
cells and equilibrium binding assays were performed.
The Bmax values for the alpha isoform were 79 þ 32
and 70 þ 26 pmol/mg protein (n = 6, NS) in the ab-
sence and presence of GK13. The Bmax values for the
beta isoform were 21 þ 4 and 14 þ 3 pmol/mg protein
(n = 6, P6 0.01) in the absence and presence of GK13.
GK13 signi¢cantly (P6 0.02) increased the a⁄nity of
both the alpha and beta isoforms of the TXA2 re-
ceptor for I-BOP (Table 1). Since the a⁄nity of the
agonist I-BOP was increased by co-transfection with
GK13, we wanted to determine if this e¡ect was
unique to I-BOP or occurred with other agonists.
Competition binding studies with ONO11113, a
TXA2 receptor agonist, and [125I]BOP were con-
ducted. Co-transfection of GK13 with either the alpha
or beta isoforms of the receptor also signi¢cantly
(P6 0.05 and P6 0.01, respectively) increased the
a⁄nity of the receptors for ONO11113 (Table 1).
Since the a⁄nity of the receptor for the agonists
was increased by co-transfection with GK13, the
question arose if there were any e¡ects of GK13 on
the a⁄nity of antagonists. Two selective TXA2 re-
ceptor antagonists SQ29,548 and L657,925, were
studied in competition binding assays. Co-transfec-
tion of GK13 with either of the two TXA2 receptor
isoforms resulted in a signi¢cant (P6 0.01) decrease
in a⁄nity of the receptors for the two antagonists
Fig. 2. PCR products obtained from human vascular smooth
muscle cells. The products shown in the ¢gure are from the
third round of ampli¢cation. See Section 2 for details. Lane 1
contains the MW standards. Lane 2 contains the products from
GSP2-532 PCR (K, predicted size = 272 bp) and lane 3 contains
the products from the GSP2-3T2 PCR (L, predicted size = 361
bp). K indicates the alpha isoform and L indicates the beta iso-
form of the TXA2 receptor. The fragments were of the pre-
dicted size and when sequenced were found to correspond to
the predicted sequences for the carboxy-terminal tails.
Table 2
IC50 values (nM) for two TXA2 receptor antagonists in the
presence or absence of GK13
TXA2 receptor isoform 3GK13 +GK13
alpha
SQ29,548 (n = 5) 8.6 þ 0.5 18 þ 1.8*
L657,925 (n = 5) 0.57 þ 0.05 1.3 þ 0.2*
beta
SQ29,548 (n = 5) 11 þ 2 21 þ 2.3*
L657,925 (n = 5) 0.57 þ 0.04 0.88 þ 0.12*
The values are presented as the mean þ S.E.M. *P9 0.01 com-
pared to the absence of GK13.
Fig. 3. I-BOP stimulated Na/H exchange in cultured rat
aortic smooth muscle cells. Increases in extracellular acidi¢ca-
tion reaction (ECAR), a measure of Na/H exchange, are in-
dicated as % increase over basal. I-BOP produced a concentra-
tion dependent increase in ECAR. See Section 2 for details.
n = 3. The data are presented as the mean þ S.E.M.
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(Table 2). Thus, co-transfection of GK13 had oppo-
site e¡ects on the receptor a⁄nity for agonists com-
pared to the antagonists.
To determine if these were non-speci¢c e¡ects of
co-transfection of a G protein alpha subunit with the
TXA2 receptors, GKi2 was co-transfected with the
receptors. GKi2 was chosen because it couples to
TXA2 receptors and is in a class of G protein sub-
units that is unrelated to GK13. The transfection of
GKi2 had no e¡ect upon the a⁄nity of the receptor
for I-BOP. For the alpha isoform, the Kd values for
I-BOP were 1.2 þ 0.2 nM without GKi2 and 1.2 þ 0.2
nM with GKi2 (n = 2), and for the beta isoform they
were 1.3 þ 0.1 nM without and 1.2 þ 0.1 nM (n = 2)
with GKi2 co-transfected, respectively.
3.4. Signal transduction
Having demonstrated the presence of GK13 and
both isoforms of the TXA2 receptor in vascular
smooth muscle cells, we wanted to determine if stim-
ulation of the receptors mediated Na/H exchange.
Rat aortic smooth muscle cells were used instead of
human cells for these experiments since they have the
high a⁄nity TXA2 receptor [3], they grow more rap-
idly than human vascular smooth muscle cells and
we have extensive experience with them and Na/H
exchange. Rat aortic smooth muscle cells were ex-
posed to increasing concentrations of I-BOP and
ECAR was measured. I-BOP produced a concentra-
tion dependent increase in ECAR (Fig. 3), which was
blocked by the TXA2 receptor antagonist, SQ29548
(data not shown).
Having established that I-BOP stimulates Na/H
exchange, we wanted to determine if this e¡ect was
mediated via GK13. Thus, CHO cells were transiently
transfected with each of the two isoforms of the
TXA2 receptors with or without GK13. I-BOP pro-
duced a concentration dependent increase in extra-
cellular acidi¢cation for both receptor isoforms (Fig.
4). The maximum responses to I-BOP were signi¢-
cantly (P = 0.04) increased for both isoforms when
GK13 was co-transfected with the receptors compared
to those where the G protein was not co-transfected.
The responses to I-BOP were blocked by the TXA2
receptor antagonist, SQ29,548 (data not shown).
Since, GKi protein subunits have been found to me-
diate Na/H exchange [26,27] and TXA2 receptors
have been shown to couple to GKi proteins, we as-
sessed the e¡ects of pertussis toxin on the responses
to I-BOP. The responses to I-BOP were not blocked
by preincubation with pertussis toxin (200 ng/ml
overnight) (Becker and Halushka, unpublished
data). In addition, in non-transfected cells, I-BOP
did not increase Na/H exchange (Becker and Ha-
lushka, unpublished data).
4. Discussion
These studies demonstrate that both isoforms of
the TXA2 receptor are present in human vascular
smooth muscle cells. When the TXA2 receptors
that were transfected into CHO cells were stimulated,
there was an increase in Na/H exchange, which
appears to be mediated in part by GK13. Evidence
is accumulating that this class of G proteins is in-
volved in cell growth [23]. Signalling via this pathway
may also be important in mediating the mitogenic
and proliferative actions of TXA2 in vascular smooth
muscle cells [15,16,32]. Indeed, Na/H exchange
may also be an early event in the activation of
ERKs, which in turn lead to mitogenic responses
[27]. While the importance of TXA2 receptor medi-
ated activation of this signalling pathway in vascular
smooth muscle cells is uncertain, a consensus has
Fig. 4. I-BOP stimulated Na/H exchange in CHO cells. In-
creases in extracellular acidi¢cation reaction (ECAR) are indi-
cated as % increase over basal. Panel A represents the alpha
isoform of the TXA2 receptor and panel B represents the beta
isoform of the TXA2 receptor. See Section 2 for details. The
co-transfection of GK13 resulted in a signi¢cant (P = 0.04) in-
crease in the ECAR for both isoforms compared to the mock
transfected cells. + = transfected with GK13, 3= mock trans-
fected. n = 4 for the alpha isoform and n = 9 for the beta iso-
form. The data are presented as the mean þ S.E.M.
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emerged to support the view that it plays an impor-
tant role in the early events of platelet activation [24].
The overall signi¢cance of the signalling of the TXA2
receptors via GK13 remains to be determined.
We have previously shown that co-transfection of
GK13 with the alpha isoform of the TXA2 receptor
resulted in a signi¢cant increase in the a⁄nity of the
receptor for I-BOP [25]. The beta isoform of the
TXA2 receptor has a longer carboxy-terminal tail,
thus it was uncertain if it could interact with GK13
and if its a⁄nity would also be a¡ected. Like the
alpha receptor isoform, GK13 increased the a⁄nity
of the beta isoform of the receptor for I-BOP. This
e¡ect of GK13 is not speci¢c for I-BOP since it ap-
pears to a¡ect agonist binding in general as evi-
denced by its ability to increase the a⁄nity of both
receptors for the agonist, ONO11113. Although the
e¡ects are small, they are consistent and have previ-
ously been reported for the alpha isoform of the
TXA2 receptor [25]. The e¡ects on the a⁄nity may
be small because the TXA2 receptors have been
transfected into a cell that has other G proteins
known to interact with the receptors and may there-
fore blunt the e¡ect. Furthermore, there appears to
be a synergistic e¡ect of GK13 with GK12 for the
alpha isoform of the TXA2 receptor [25]. Whether
this occurs with the beta isoform is unknown.
Our detection of GK13 and the mRNA for both
TXA2 receptor isoforms in human vascular smooth
muscle cells raises the possibility that the vascular
subtype may be the result of interactions of the re-
ceptor with distinct G protein K subunit(s). Thus, in
those cells where the high a⁄nity subtype of TXA2
receptor exists, it may gain its subtype characteristics
from an interaction with one or more G protein K
subunits. However, this notion has to be tempered
somewhat, since in the current experiments GK13 co-
transfection did not decrease the Kd to the same
values commonly seen for the high a⁄nity state.
Evidence has accumulated to support the view that
the interaction of receptors with speci¢c G protein K
subunits may alter the binding a⁄nity of ligands to
the receptor. That there is some speci¢city for this
e¡ect of GK13 is borne out by the observation that
GKi2 did not a¡ect the a⁄nity of the receptors for I-
BOP. Allan et al. [25] previously found that GKq also
increased the a⁄nity of the alpha isoform for I-BOP,
and we found a similar result for the beta isoform
(data not shown). 5HT1A receptor a⁄nity for its ag-
onist [3H]8-OH-DPAT was increased by co-expres-
sion of it with GKi1 [33]. One example of this for
another eicosanoid receptor is the EP3 receptor
which has a least four di¡erent carboxy-terminal
tail splice variants [34^36]. Coupling of one of the
variants to GKi or GKs resulted in di¡erences in the
a⁄nity of PGE2 for the receptor [37]. A similar ob-
servation has been made for the PACAP receptor
that has ¢ve splice variants [38]. Thus, the possibility
exists that splice variants of receptors not only cou-
ple selectively to speci¢c G protein K subunits, but
the coupling in turn changes the a⁄nity of the re-
ceptor for agonist or antagonist ligands. This in turn
can give rise to apparent subtypes of receptors. It
may also serve as a possible explanation for why
splice variants of G protein coupled receptors exist.
We also found that co-transfection of the two re-
ceptors with GK13 decreased the a⁄nity of the recep-
tors for antagonists, the opposite e¡ect of that seen
for the agonists. It has previously been demonstrated
that incubation of receptors with stable guanine nu-
cleotides can have a di¡erential e¡ect on the a⁄nity
of biogenic amine receptors for agonists and antag-
onists [39]. To our knowledge this is the ¢rst demon-
stration of a G protein K subunit having a di¡eren-
tial e¡ect on the a⁄nity of agonists and antagonists
without the addition of a stable GTP analogue. This
e¡ect may be unique to the GK12 class of G proteins
or may extend to other closely related classes such as
GKq.
Le¡ et al. [40] have postulated a three state recep-
tor model of agonist action. In their model, they
propose that di¡erences in agonist potency and e⁄-
cacy, which would have been attributed to subtypes
of receptors in the past, may be due to di¡erences in
receptor-G protein interactions. The data presented
herein are consistent with their model and support
the notion that the previously described TXA2 recep-
tor subtypes based on pharmacological criteria may
result from unique receptor-G protein interactions.
Clearly, further studies are required to test this hy-
pothesis, which may provide a unique mechanism for
the development of receptor subtypes.
In summary, the alpha and beta isoforms of the
TXA2 receptor couple to GK13 as demonstrated by
changes in agonist and antagonist a⁄nity and signal-
ling. The results raise the possibility that TXA2 re-
ceptor subtypes arise from the unique interactions of
the receptor isoforms with the distinct G protein K
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subunits. Clearly, these notions need to be further
tested.
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